WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”) 510(k) clearance submission for its revyve® Antimicrobial Wound Cleanser. revyve Antimicrobial Wound Cleanser is the Company’s third product in its revyve product line and complimentary to Kane’s revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray products. This new companion product will be part ...

核心观点 - Kane Biotech在北美两大伤口护理会议上展示revyve抗菌伤口凝胶的临床前数据和临床案例观察 显示该产品在抑制关键蛋白酶和促进慢性伤口愈合方面具有显著潜力 [1][2][6] 临床前数据表现 - revyve在体外实验中显示对基质金属蛋白酶(MMP)活性抑制达80% [7] - 对弹性蛋白酶活性抑制达82% [7] - 对胶原酶和TACE酶活性实现100%完全抑制 [7] - 慢性伤口中肿瘤坏死因子-α(TNF-α)水平可能比急性伤口高出100倍 [2] 临床案例观察结果 - 使用revyve 6-12周的慢性伤口患者出现伤口尺寸减小和组织再生改善 [6] - 压力性伤口三周内观察到伤口尺寸减小和生活质量改善 [8] - 静脉性腿部溃疡两个月内伤口尺寸减少60% [8] - 疼痛性压力性伤口报告疼痛消除和渗出液减少 [8] - 静脉性腿部溃疡六周内显示愈合进展和疼痛改善 [8] 学术会议参与情况 - 在NSWOCC加拿大第44届全国会议上展示四个案例研究海报并进行口头报告 [3] - 在美国最大伤口护理会议SAWC春季会议上展示临床前数据 [2] - 会议期间 healthcare professionals与公司代表直接交流并参与产品演示 [5] 产品与市场发展 - revyve已获得加拿大卫生部批准 在真实患者复杂慢性伤口案例系列中显示将不愈合伤口转为愈合伤口 [4] - 公司正在开发针对生物膜和伤口细菌的新型伤口护理治疗方法 [9] - 这些展示是revyve市场支持计划的扩展 证明其临床价值和商业潜力 [9]

For additional information, please visit https://www.vaporox.com/. About MIMEDX "Vaporox is excited to partner with a market leader in wound care to expand awareness and adoption of our technology," said Alan Sage, Chief Executive Officer of Vaporox. "We believe co-promotion with MIMEDX will accelerate our market penetration and create a synergistic offering—allowing us to reach more patients with these highly complementary offerings." VHT has been the subject of three IRB clinical studies, each of which de ...